CASE REPORTS
CASE SERIES

Background: The use of disease modifying treatments (DMTs) in multiple sclerosis (MS) has been well studied and has shown to …

Background:: Eculizumab is a long-acting humanized monoclonal antibody targeted against complement C5. By preventing the cleavage of C5 into C5a …

Background: There is increased prevalence of genetic testing within the field of neurology and provider awareness of genetic conditions mimicking …

Background: Bilateral involvement and severe visual impairment can occur in the acute phase of pediatric myelin oligodendrocyte glycoprotein (MOG) antibody-associated …

Background: High-dose corticosteroids (CS) (1g IV methylprednisolone or 1250 mg oral prednisone for 3-5 days) is the most common treatment …

Background: COVID 19 virus can infect the central and peripheral nervous system with or without other systemic manifestations of infection. …

Background: Spasticity is present among 60-80% of individuals with Multiple Sclerosis (Etoom et al, 2018). One-third of people with Multiple …

Background: The association of multiple sclerosis (MS) and neurofibromatosis type 1 (NF1) has been rarely reported. Objectives: To report a …

Background: MOG antibody-associated disease (MOGAD) is an inflammatory demyelinating disorder characterized by IgG antibodies against myelin oligodendrocyte glycoprotein (MOG). Distinct …

Background: There is a need for exercise strategies that maximize motor function and related changes in the central nervous system …

Background: Multiple sclerosis (MS) is the most common autoimmune demyelinating disease of the central nervous system (CNS). It is an …

Background: Tinea corporis is a fungal infection of the skin excluding the face, hands, feet, scalp, nail, or groin. It …